About GQ Bio
GQ Bio is a company based in Hamburg (Germany) founded in 2012 was acquired by Pacira in February 2025. The company has 2 employees as of December 31, 2022. GQ Bio offers products and services including Gene Therapy Vector Platform and Transformative Medicines. GQ Bio operates in a competitive market with competitors including Flexion Therapeutics, Formation Bio, Rocket Pharma, Eupraxia Pharmaceuticals and MRM Health, among others.
- Headquarter Hamburg, Germany
- Employees 2 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Gq Bio Therapeutics Gmbh
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GQ Bio
GQ Bio offers a comprehensive portfolio of products and services, including Gene Therapy Vector Platform and Transformative Medicines.
Enables efficient delivery of large genes for chronic diseases.
Develops treatments for conditions like osteoarthritis.
Funding Insights of GQ Bio
Investors in GQ Bio
GQ Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Pacira.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Injectable non-opioid products for post-surgical pain control are developed.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GQ Bio
Financial Statements - GQ Bio
Gq Bio Comparisons
Competitors of GQ Bio
GQ Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Formation Bio, Rocket Pharma, Eupraxia Pharmaceuticals and MRM Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
AI-powered drug discovery platform for various diseases
|
|
| domain | founded_year | HQ Location |
Gene-modified cell therapies for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Sustained-release drug delivery platform for osteoarthritis therapies is developed.
|
|
| domain | founded_year | HQ Location |
Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases
|
|
| domain | founded_year | HQ Location |
Oligonucleotide therapies for neuromuscular diseases like Myotonic Dystrophy are developed.
|
Latest news on Gq Bio
Frequently Asked Questions about GQ Bio
GQ Bio was founded in 2012.
GQ Bio is headquartered in Hamburg, Germany. It is registered at Hamburg, Hamburg, Germany.
Kilian Guse is the current CEO of GQ Bio.
As of Dec 31, 2022, the latest employee count at GQ Bio is 2.
Developer of gene therapies for orthopedic treatment. It offers a gene therapy vector platform that develops transformative medicines which include GQ-501, GQ-401, and GQ-203 to treat chronic diseases such as osteoarthritis and intervertebral disc degeneration.
GQ Bio's top competitors include Flexion Therapeutics, Formation Bio and Eupraxia Pharmaceuticals.
GQ Bio offers Gene Therapy Vector Platform and Transformative Medicines.
GQ Bio has 1 investor. Key investors include Pacira.